Weiping Zou

Weiping Zou, M.D., Ph.D.

Charles B. de Nancrede Professor; Professor of Surgery, Immunology, and Biology
Director, Center of Excellence for Cancer Immunology and Immunotherapy
Co-Director, Cancer Hematopoiesis and Immunology Program
Director, Translational Research; Co-Director, Immune Monitoring Core
Accepting Students?


Weiping Zou is a scientist noted for his work regarding understanding the nature of human tumor immune responses and developing mechanism-informed combination therapies for cancer. He has developed an international reputation in human tumor immunosuppressive mechanisms in the tumor microenvironment.

Research Interests

Tumor immunology and immunotherapy, with an emphasis on cross-talk among immune cell subsets, stromal cells, tumor cells and tumor stem cells in the tumor microenvironment, and its impact on tumor immunity, tolerance and therapy.


Li J, W. W., Zhang Y, Cieślik M, Guo J, Tan M, Green MD, Wang W, Lin H, Li W, Wei S, Zhou J, Li G, Jing X, Vatan L, Zhao L, Bitler B, Zhang R, Cho KR, Dou Y, Kryczek I, Chan TA, Huntsman D, Chinnaiyan AM, Zou W. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. J Clin Invest, doi:10.1172/JCI134402 (2020).

Wang, W. et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569, 270-274, doi:10.1038/s41586-019-1170-y (2019).

Lin, H. et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest 128, 805-815, doi:10.1172/JCI96113 (2018).

Maj, T. et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol, doi:10.1038/ni.3868 (2017).

Wang, W. et al. Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell 165, 1092-1105 (2016).

Zhao, E. et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol 17, 95-103 (2016).

Peng, D. et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249-253 (2015).

Kryczek, I. et al. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 40, 772-784, doi:10.1016/j.immuni.2014.03.010 (2014).

Cui, T. X. et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 39, 611-621, doi:10.1016/j.immuni.2013.08.025
S1074-7613(13)00377-4 [pii] (2013).

Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10, 942-949, doi:10.1038/nm1093
nm1093 [pii] (2004).

Curiel, T. J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9, 562-567 (2003).

Research Opportunities for Rotating Students